Navigation Links
Nephros, Inc. Completes $1.25 Million Private Placement
Date:7/30/2009

RIVER EDGE, N.J., July 30 /PRNewswire-FirstCall/ -- Nephros, Inc. (OTC Bulletin Board: NEPH), a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification, today reported that it has completed a private placement of shares of its common stock and warrants to purchase additional common stock for aggregate proceeds of approximately $1.25 million.

"Nephros is pleased to have completed this financing, which was led by existing shareholders and represents what we believe is modest dilution of the company's current shareholder base," said Ernest Elgin, Chief Executive Officer. "These funds strengthen the company's balance sheet and provide working capital as we launch the company's recently FDA approved Dual Stage Ultrafilters and prepare to launch the company's OLpur MD220 Dialyzers and H2H Hemodiafiltration Module when approved in the U.S."

The securities sold in the private placement have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration under such act and applicable state securities laws or an applicable exemption from those registration requirements. Nephros has agreed to file a registration statement covering the resale of the shares issued in the private placement, including the shares issuable upon exercise of the warrants. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Nephros, Inc.

Nephros, Inc., headquartered in River Edge, New Jersey, is a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification.

The Nephros hemodiafiltration ("HDF") system is designed to improve the quality of life for the End-Stage Renal Disease (ESRD) patient while addressing the critical financial and clinical needs of the care provider. ESRD is a disease state characterized by the irreversible loss of kidney function. The Nephros HDF system removes a range of harmful substances more effectively, and with greater capacity, than existing ESRD treatment methods, particularly with respect to substances known collectively as "middle molecules." These molecules have been found to contribute to such conditions as dialysis-related amyloidosis, carpal tunnel syndrome, degenerative bone disease and, ultimately, mortality in the ESRD patient. Nephros ESRD products are sold and distributed throughout Europe and are currently being used in over fifty clinics in Europe.

The Nephros Dual Stage Ultra-filter (DSU) is the basis for Nephros's line of water filtration products. The patented dual stage cold sterilization ultrafilter has the capability to filter out bacteria and, due to its exceptional filtration levels, filter out many viruses, parasites and biotoxins. Sale of the DSU has begun at several major U.S. medical centers for infection control and has been selected for further development by the U.S. Marine Corps for purification of drinking water by soldiers in the field.

For more information on Nephros, please visit its website athttp://www.nephros.com/.

Forward-Looking Statements

Statements in this news release that are not historical facts constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Such statements may be preceded by words such as "may," "plans," "expects," "believes," "hopes," "potential" or similar words. For such statements, Nephros claims the protection of the PSLRA.

Forward-looking statements are not guarantees of future performance, are based on assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond Nephros' control. Actual results may differ materially from the expectations contained in the forward-looking statements. Factors that may cause such differences include the risks that Nephros may not be able: (i) to obtain additional funding when needed or on favorable terms; (ii) to continue as a going concern; (iii) to obtain appropriate or necessary governmental approvals to achieve its business plan or effectively market its products; (iv) to have its technologies and products accepted in current or future target markets; (v) to demonstrate in pre-clinical or clinical trials the anticipated efficacy, safety or cost savings of products that appeared promising to Nephros in research or clinical trials; or (vi) to secure or enforce adequate legal protection, including patent protection, for its products. More detailed information about Nephros and the risk factors that may affect the realization of forward-looking statements is set forth in Nephros' filings with the SEC, including Nephros' Annual Report on Form 10-K for the fiscal year ended December 31, 2008. Investors and security holders are encouraged to read these documents on the SEC's website athttp://www.sec.gov/. Nephros does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.


'/>"/>
SOURCE Nephros, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Nephros, Inc. Receives the 2009 Frost & Sullivan Medical Device Patient Care Company of the Year Award
2. Cardium Completes Sale of InnerCool Therapies Business to Royal Philips Electronics
3. Genstar Capital Portfolio Company Univita Health Completes Debt Financing
4. Nuvilex Completes First Sale of Last Shot Hangover Remedy(TM)
5. meridianEMR Completes Surescripts(R) Certification
6. Hard To Treat Diseases (HTDS.PK) Completes India Order
7. Transdel Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study for Novel Topical Pain Treatment
8. Riverside Partners Completes Growth Equity Investment in Vocollect, the Leader in Voice Solutions for Supply-Chain and Healthcare Workforce Management
9. Jazz Pharmaceuticals Completes $7 Million Private Placement
10. Everock, Inc. Completes Reverse Merger with Privately Held All-Natural Food Producer, Natures Peak
11. Prince William Health System Completes Merger With Novant Health to Expand Quality Health Care in Northern Virginia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... GeBBS Healthcare ... Assurance, at HCCA’s 21st annual Compliance Institute on March 26-28 in National Harbor, ... for all medical chart types with a comprehensive set of features including built-in ...
(Date:3/23/2017)... ... ... Woman Be Ye Healed-Passing On A Legacy”: a call to heal the wounded Church. ... author, Desiree M Webb, a registered nurse, minister of music, speaker, songwriter, recording artist, ... husband, Paul, for over twenty-nine years. Desiree enjoys writing, beach trips, ministering in ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... the existence of God. “A Respectful Response To Atheist Manifesto” is the creation ... married to his wife, Nancy, for sixty years. He holds graduate degrees from ...
(Date:3/23/2017)... ... March 23, 2017 , ... Vortex Biosciences, provider ... protein expression in circulating tumor cells using microfluidic western blotting” in Nature Communications ... Vortex technology to capture CTCs and a microfluidic single-CTC resolution Western ...
(Date:3/22/2017)... ... March 23, 2017 , ... Catalent Pharma Solutions, ... biologics and consumer health products, today announced that it had won the ‘Clinical ... at the Suntec Singapore International Exhibition & Convention Centre, Singapore. The award was ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... NORTH CHICAGO, Ill. , March 23, 2017 /PRNewswire/ ... actress, dancer and Emmy Award-winning choreographer Julianne Hough ... a campaign called "Get in the Know about ME ... AbbVie, is dedicated to inspiring women to learn about ... in 10 women, 1 and to address their ...
(Date:3/23/2017)... , March 23, 2017 ... presented in Brussels , My ... change bad sun habits into life-saving ones, was ... Association (AIM). Launched in 2016, the "Nudging for ... it easy and desirable for people to change ...
(Date:3/22/2017)... Mar. 22, 2017 Research and Markets has ... Analysis & Trends - Industry Forecast to 2025" report to ... ... a CAGR of around 10.9% over the next decade to reach ... analyzes the market estimates and forecasts for all the given segments ...
Breaking Medicine Technology: